The Use of Ultra-Low PSA in Specific Patient Profiles

EP: 1.An Overview of the ARANOTE Trial

EP: 2.Comparing Trials Studying Treatment Intensification In mHSPC

EP: 3.Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

EP: 4.Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

EP: 5.Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

EP: 6.Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

EP: 7.Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

EP: 8.Using Ultrasensitive PSA Assays in Routine Practice

Now Viewing

EP: 9.The Use of Ultra-Low PSA in Specific Patient Profiles

EP: 10.Selecting Between Receptor Pathway Inhibitors for mHSPC

Patient Selection for Ultra-Low PSA Monitoring

Key Themes:

• Identification of patient profiles most likely to benefit from ultra-low PSA monitoring
• Relevance for specific risk categories
• Potential applications in high-volume disease or triplet therapy

Expert Insights:

• Dr Shore identified specific patient profiles or risk categories where the ultra-low PSA threshold might be particularly valuable.

He discussed its potential relevance for patients with high-volume disease, those receiving triplet therapy, or patients demonstrating rapid initial PSA declines.